Last Price$3.7(6.6%)
Market Cap$253.4M
CMPS Intrinsic Value
Intrinsic Value of CMPS Overview
Key Highlights:
As of Mar 03, 2025 CMPS Relative Value is $2.6, which is overvalued by 28.8%, compared to current share price of $3.7.
As of Mar 03, 2025 CMPS DCF Value is N/A, which is undervalued by N/A, compared to current share price of $3.7.
CMPS Historical Intrinsic Value
Crunching data... Almost there!
Crunching data... Almost there!
CMPS Valuation Metrics
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
21.5x (as of Mar 03, 2025)
EV/Gross Profit
46.0x (as of Mar 03, 2025)
EV/EBIT
(0.5x) (as of Mar 03, 2025)
EV/EBITDA
(0.5x) (as of Mar 03, 2025)
EV/FCF
(0.8x) (as of Mar 03, 2025)
EV/OCF
(0.8x) (as of Mar 03, 2025)
P/Revenue
68.8x (as of Mar 03, 2025)
P/Gross Profit
147.6x (as of Mar 03, 2025)
P/EBIT
(1.5x) (as of Mar 03, 2025)
P/EBITDA
(1.7x) (as of Mar 03, 2025)
P/FCF
(2.4x) (as of Mar 03, 2025)
P/OCF
(2.4x) (as of Mar 03, 2025)
P/E
(1.8x) (as of Mar 03, 2025)
P/BV
1.3x (as of Mar 03, 2025)
PEG 1Y
(0.9x) (as of Mar 03, 2025)
CMPS DCF Model
Free Cash Flow to Firm Model
NOPAT Model
Free Cash Flow to Equity Model
Net Income Model
Millions
Billions
| Dec'19 Actual | Dec'20 Actual | Dec'21 Actual | Dec'22 Actual | Dec'23 Actual | Dec'24 Estimate | Dec'25 Estimate | Dec'26 Estimate | Dec'27 Estimate | Dec'28 Estimate | Dec'29 Estimate | Dec'30 Estimate | Dec'31 Estimate | Dec'32 Estimate | Dec'33 Estimate | Dec'34 Terminal | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 (100.0%) | 0.0 (100.0%) | 0.0 (100.0%) | 0.0 (100.0%) | 0.0 (100.0%) | 0.0 (100.0%) | 0.0 (100.0%) | 0.0 (56,000,100.0%) | 0.0 1,769.1% | 0.0 1,522.3% | 0.0 1,269.1% | 0.0 1,015.9% | 0.0 762.7% | 0.0 509.4% | 0.0 256.2% | 0.0 3.0% |
% margin | (21.2) 0.0% | (51.4) 0.0% | (83.2) 0.0% | (110.4) 0.0% | (136.9) 0.0% | 0.0 N/A | 0.0 N/A | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
NOPAT % effective tax rate | (21.2) N/A | (51.4) N/A | (83.5) N/A | (110.9) N/A | (137.8) N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A |
% of revenue | 0.1 N/A | 0.1 N/A | 0.2 N/A | 0.3 N/A | 0.2 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A |
% of revenue | (0.2) N/A | (0.1) N/A | (0.3) N/A | (0.6) N/A | (0.1) N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A |
% of revenue | (2.7) N/A | (0.7) N/A | (6.6) N/A | (30.7) N/A | 3.5 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A |
Free Cash Flow to Firm (FCFF) % of revenue | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A | 0.0 N/A |
% of FCFF used in calculation | ||||||||||||||||
Discount period | ||||||||||||||||
Discount factor | ||||||||||||||||
Discounted FCFF (DFCFF) |
CMPS DCF Value
Crunching data... Almost there!
CMPS Earnings Power Value and Enterprise Value
Annual
LTM
Enterprise Value Breakdown
EPV and MIVoG as % of EV
CMPS Reverse DCF
Implied FCF growth
Implied Revenue growth
Reverse DCF Assumptions and Outputs
as of Sep 30, 2024
(105.3M)
Long-Term growth rate
3.0%
FX rate
1.0
Last share price
6.3
Implied FCF growth 1-10Y
0.0%
Implied Free Cash Flow growth vs Historical average vs Industry growth
Competing with CMPS Intrinsic Value
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Enterprise Value | Intrinsic Value | DCF Value | Relative value | Ben Graham Revised fair value | Peter Lynch fair value | Earnings Power Value (EPV),
% of EV | Market-Implied Value of Growth (MIVoG),
% of EV | Reverse DCF (implied FCF growth) | Reverse DCF (implied Revenue growth) |
$253.4M | $79.0M | $2.6 30.5% overvalued | N/A | $2.6 30.5% overvalued | Negative 560.6% overvalued | $8.2 123.5% undervalued | N/A | N/A | 0.0% | 0.0% | |
$78.9B | $83.6B | $368.8 18.5% undervalued | $256.4 18.0% overvalued | $481.2 54.6% undervalued | $332.4 6.8% undervalued | $255.6 17.9% overvalued | 133.2% | (33.2%) | (4.4%) | (4.2%) | |
$14.6B | $24.6B | $71.8 204.9% undervalued | $110.0 367.0% undervalued | $33.7 43.0% undervalued | $9.3 60.4% overvalued | $9.7 58.9% overvalued | 88.1% | 11.9% | (24.5%) | (21.1%) | |
$12.2B | $22.8B | $329.6 130.3% undervalued | $495.8 246.0% undervalued | $163.4 14.2% undervalued | $94.5 34.0% overvalued | $125.9 12.0% overvalued | 149.9% | (49.9%) | (18.7%) | (18.1%) | |
$12.0B | $22.2B | $378.2 203.6% undervalued | $501.3 302.0% undervalued | $255.1 104.8% undervalued | Negative 1,422.2% overvalued | Negative 1,280.8% overvalued | 203.2% | (103.2%) | (11.0%) | (17.5%) | |
$11.7B | $16.6B | $315.7 79.6% undervalued | $314.1 79.0% undervalued | $317.3 80.5% undervalued | Negative 101.8% overvalued | $554.5 215.4% undervalued | 102.0% | (2.0%) | (7.7%) | (5.9%) | |
$10.0B | $10.3B | $72.1 27.8% overvalued | $65.3 35.0% overvalued | $78.9 21.0% overvalued | $45.5 54.5% overvalued | $37.6 62.3% overvalued | 82.8% | 17.2% | 3.9% | 5.0% | |
$8,767.7M | $8,730.2M | $397.3 32.8% overvalued | $502.3 15.0% overvalued | $292.2 50.6% overvalued | $594.4 0.5% undervalued | $357.3 39.6% overvalued | 46.3% | 53.7% | 1.9% | 3.8% | |
$7,406.8M | $8,868.6M | $95.8 26.2% overvalued | $119.4 8.0% overvalued | $72.3 44.3% overvalued | $107.9 16.9% overvalued | $73.4 43.5% overvalued | 40.4% | 59.6% | 8.3% | 7.4% | |
$5,760.8M | $5,348.3M | $24.0 29.4% overvalued | $17.1 50.0% overvalued | $30.9 9.0% overvalued | Negative 117.5% overvalued | Negative 120.3% overvalued | 63.2% | 36.8% | (2.6%) | (1.6%) | |
$2,714.5M | $4,722.4M | $40.8 39.3% undervalued | N/A | $40.8 39.3% undervalued | Negative 12,430.7% overvalued | N/A | 225.0% | (125.0%) | (100.0%) | (100.0%) |
Intrinsic Valuation Tools
Wondering how to calculate intrinsic value of a stock? Use our intrinsic value tools to simplify complex valuation concepts and save time.